Akorn Pharmaceuticals, a generic and brand drug manufacturer, is giving 340B covered entities refunds for overcharges on 24 NDCs from Jan. 1, 2019, through Dec. 31, 2021.
The U.S. Health Resources and Services Administration (HRSA) posted Akorn’s notice to entities on its website this week. A HRSA fiscal year 2021 audit found that Akorn “did not determine the difference between new drug price estimates and the actual 340B ceiling price and offer a refund.” HRSA also found that the company “did not submit quarterly pricing data to 340B OPAIS,” the 340B program database.
Akorn Pharmaceuticals, a generic and brand drug manufacturer, is giving 340B covered entities refunds for overcharges on 24 NDCs from Jan. 1, 2019, through Dec. 31, 2021.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
